FORT LEE, N.J., April. 29, 2024 — Kedrion Biopharma Inc., an international biopharmaceutical company specializing in the research and development, production, and commercialization of plasma-derived therapeutic products used in treating rare and serious diseases, announced today that plasminogen deficiency type 1 (PLGD-1) patients in the U.S. now have access to RYPLAZIM® (plasminogen, human-tvmh).
RYPLAZIM® is the first and only FDA-approved treatment for the approximately 500 people in the U.S. affected by plasminogen deficiency type 1 (PLGD-1). PLGD-1 is an ultra-rare disease that leads to reduced plasminogen activity levels in the body, often resulting in fibrinous lesions on various organs. About 81% of the patients develop lesions on one or both eyes as their lead symptom, but lesions can develop throughout the body on all organs with mucous membranes. Patients with PLGD-1 may require lifelong treatment.
“RYPLAZIM® brings hope and relief to PLGD-1 patients of all ages who have long awaited effective treatment options,” said Bob Rossilli, Chief Commercial Officer, Global Business of Kedrion Biopharma. “We are expediting production and distribution to patients and are proud to provide adult and pediatric patients with the first and only FDA-approved treatment designed specifically to address plasminogen deficiency”
The FDA’s clearance of RYPLAZIM® sets the stage for Kedrion to pursue additional regulatory approvals in other countries worldwide. It is the latest example of the company’s commitment to expanding access to life-changing drugs to rare disease patients globally.
To learn more about RYPLAZIM® and PLGD-1, please visit: ryplazim.com or plasminogen.com
###
About Kedrion
Kedrion Biopharma is an international biopharmaceutical company specializing in the research and development, production, and commercialization of plasma-derived therapeutic products for use in treating and preventing serious diseases, disorders, and conditions like plasminogen deficiency, hereditary factor X deficiency, and hemophilia. Its portfolio of 37 life-saving products is distributed in over 100 countries.